Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
HCW Biologics Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5810(c)(3)(A)).
- Exchange
- nasdaq
- Notice
- hearing update
- Deficiency
- minimum bid price
- Rules
- 5810(c)(3)(A)
Exact text from the filing
ously disclosed, on February 5, 2025, the Company received written notice from the Staff that its securities were subject to delisting from Nasdaq since the Company did not regain compliance with the requirement to maintain a minimum bid price of $1 per share, in accordance with Nasdaq Listing Rule 5810(c)(3)(A) (“Bid Price Rule”) and the requirement to maintain the minimum $15,000,000 market value of publicly held securities (“MVPHS”) threshold required for continued listing on The Nasdaq Global Market ® under Nasdaq Listing Rule 5450(b)(2)C) (the “MVPHS Rule”). On March 3, 2025, the Panel gr
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
HCW Biologics Inc. received a nasdaq hearing update notice regarding market value (rules 5450(b)(3)(A), 5450(b)(2)(C)).
- Exchange
- nasdaq
- Notice
- hearing update
- Deficiency
- market value
- Rules
- 5450(b)(3)(A), 5450(b)(2)(C)
Exact text from the filing
arket LLC (“Nasdaq” or the “Exchange”) that its securities were subject to delisting from Nasdaq since the Company did not regain compliance with the $50,000,000 market value of listed securities (“MVLS”) threshold required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A) (the “MVLS Rule”). The Company made a timely request for a hearing before the Nasdaq Hearings Panel (the “Panel”) and was granted a hearing date on February 13, 2025. As previously disclosed, on February 5, 2025, the Company received written notice from the Staff that its securities we
View on SEC.gov